Načítá se...
GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets
Pancreatic cancer has one of the highest mortality rates (5‐year survival ~9%) among cancers. Pancreatic adenocarcinoma (PAAD) is the most common (>80%) and the most lethal type of pancreatic cancer. A need exists for new approaches to treat pancreatic adenocarcinoma. GPCRs, the largest family of...
Uloženo v:
| Vydáno v: | Br J Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7205828/ https://ncbi.nlm.nih.gov/pubmed/32060895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15028 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|